[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349076-105":59,"doc-detail-349076-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","gaps-and-paths-forward-in-cancer-pharmacology-and-translational-research-review","Gaps and paths forward in cancer pharmacology and translational research - review","","Cancer drug development faces high failure rates when transitioning from preclinical studies to clinical trials, creating a persistent “valley of death” between laboratory findings and patient benefit. This review frames drug translation as a non-linear, continuously refined process to reduce false-positive outcomes and support underserved patient populations. It summarizes traditional pharmacokinetic and pharmacodynamic evaluation approaches and highlights PK-PD modeling of tumor growth inhibition as a strategy to improve understanding of drug efficacy and the accuracy of clinical translation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/gaps-and-paths-forward-in-cancer-pharmacology-and-translational-research-review/349076/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/gaps-and-paths-forward-in-cancer-pharmacology-and-translational-research-review/349076.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the “valley of death” in cancer drug development?","Question",{"text":112,"@type":113},"It is the gap between preclinical laboratory research and clinical translation, where most drugs fail during the transition to clinical trials.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do many oncology drugs fail despite promising preclinical profiles?",{"text":117,"@type":113},"Failure can stem from multiple, case-dependent reasons, including lack of clinical efficacy, off-target toxicity, suboptimal pharmacokinetic parameters, and insufficient funding.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review propose improving translational success?",{"text":121,"@type":113},"By treating drug development as a dynamic, iterative process rather than a purely linear one, using continual refinement and more informative PK-PD approaches.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349076,1790740587,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","OPEN ACCESS  \nEDITED BY  \nQingbin Cui,  \nUniversity of Toledo College of Medicine and Life Sciences, United States  \nREVIEWED BY  \nSitaramaraju Adduri,  \nUniversity of Texas at Tyler, United States Anand Giddabasappa,  \nPfizer, United States  \n*CORRESPONDENCE  \nEugene F. Douglass Jr,  [ed29157@uga.edu](ed29157@uga.edu)  \nRECEIVED 31 December 2025  \nREVISED 25 February 2026  \nACCEPTED 02 March 2026  \nPUBLISHED 10 April 2026  \nCITATION  \nHughes EA, Davenport LL, Zdyrski C, Pawlak A, Mochel JP, Douglass EF Jr (2026) Gaps and paths forward in cancer pharmacology and translational research. Front. Pharmacol. 17:1779049 .  \ndoi: 10.3389/fphar.2026.1779049  \nCOPYRIGHT  \n© 2026 Hughes, Davenport, Zdyrski, Pawlak, Mochel and Douglass. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTYPE Review  \nPUBLISHED 10 April 2026  \nDOI 10.3389/fphar.2026.1779049  \nGaps and paths forward in cancer pharmacology and translational research  \nElizabeth A. Hughes 1, Lindsay L. Davenport 1,  \nChristopher Zdyrski 2, Aleksandra Pawlak 3,4, Jonathan P. Mochel 2 and Eugene F. Douglass Jr 1*  \n1Pharmaceutical and Biomedical Science, College of Pharmacy, UGA, Athens, GA, United States, 2Precision One Health Initiative, Department of Pathology, College of Veterinary Medicine, Athens, GA, United States, 3Precision One Health Initiative, Department of Physiology and Pharmacology, College of Veterinary Medicine, Athens, GA, United States, 4Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland  \nAs drug development costs continue to rise, there is a need to reframe how drug efficacy is evaluated in preclinical models to reduce the rate of false positives. The“valley of death” refers to the gap between bench research and clinical translation. In particular, oncology chemotherapies have the highest rate of drug failure compared to other drug classes. While there has been progress in overall cancer survival, some cancers and patient populations still have a poor prognosis. To bridge the gaps of drug failure and aid underserved patient populations, drug translation cannot be viewed as a purely linear process, but one in which continual refinement is used to create more efficacious drug candidates. Additionally, pharmacokinetic-pharmacodynamic modeling could prove instrumental in better understanding drug efficacy in cellular models and in evaluating clinical translation potential with greater accuracy. The path forward in clinical pharmacology is to view drug development and efficacy as a dynamic process rather than a purely linear fashion. This review discusses traditional pharmacodynamic and pharmacokinetic evaluation methods, as well as pharmacokinetic-pharmacodynamic models of tumor growth inhibition.  \nKEYWORDS  \ncancer drug discovery and development, drug efficacy, PK-PD (pharamacokineticpharmacodynamic) model, translational gap, translational medicine  \nIntroduction  \nMost drugs fail during the transition from preclinical research to clinical trials, resulting in a gap between laboratory research and patient care. The gap is often called the “valley of death,” where approximately 90% of drugs fail in clinical development following preclinical development, with 40%–50% failing due to a lack of clinical efficacy (Figure 1A) (Seyhan, 2019; Sun et al., 2022; Sorger, 2011) . Even drugs that have optimal selectivity for target binding and are deemed ideal candidates can fail in clinical trials (Figure 1A). According to a 2011 NIH White Paper by the Quantitative and Systems Pharmac","cbCait6Ati5n7ubG","https://ap.wps.com/l/cbCait6Ati5n7ubG","pdf",3810825,15,"English","# Introduction\n## The “valley of death” and why drugs fail\n## Translational challenges from bench to bedside\n## Incorporating PK/PD and biomarkers in early oncology trials","[{\"question\":\"What is the “valley of death” in cancer drug development?\",\"answer\":\"It is the gap between preclinical laboratory research and clinical translation, where most drugs fail during the transition to clinical trials.\"},{\"question\":\"Why do many oncology drugs fail despite promising preclinical profiles?\",\"answer\":\"Failure can stem from multiple, case-dependent reasons, including lack of clinical efficacy, off-target toxicity, suboptimal pharmacokinetic parameters, and insufficient funding.\"},{\"question\":\"How does the review propose improving translational success?\",\"answer\":\"By treating drug development as a dynamic, iterative process rather than a purely linear one, using continual refinement and more informative PK-PD approaches.\"}]","Gaps and paths forward in cancer pharmacology and translational research - review | PDF",1790081517,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33c805a3e655a1591eea16a69970bf25.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/692f57db2a8265a6995df3bd41af8265.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1fe5a77823423f1768325bd81228054c.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af488f5fe510e080d799497d55302d28.webp",980,1385]